AZN.UK

11,926

-0.52%↓

GSK

1,489.5

+2.02%↑

AZN.UK

11,926

-0.52%↓

GSK

1,489.5

+2.02%↑

AZN.UK

11,926

-0.52%↓

GSK

1,489.5

+2.02%↑

AZN.UK

11,926

-0.52%↓

GSK

1,489.5

+2.02%↑

AZN.UK

11,926

-0.52%↓

GSK

1,489.5

+2.02%↑

Search

PureTech Health Plc

Fermé

116 -1.36

Résumé

Variation du prix de l'action

24h

Actuel

Min

103

Max

117.6

Chiffres clés

By Trading Economics

Revenu

70M

Ventes

4M

P/E

Moyenne du Secteur

9.369

35.733

BPA

0.39

Marge bénéficiaire

1,727.216

Employés

56

EBITDA

102M

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

301M

Ouverture précédente

117.36

Clôture précédente

116

PureTech Health Plc Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

8 sept. 2025, 23:59 UTC

Acquisitions, Fusions, Rachats

Anglo American Is in Talks to Buy Teck Resources, Bloomberg Says

8 sept. 2025, 22:02 UTC

Principaux Mouvements du Marché

Microsoft Signs $17.4 Billion AI Deal With Nebius

8 sept. 2025, 17:01 UTC

Principaux Mouvements du Marché

Eightco Holdings Stock Surges as Dan Ives Joins Board Amid Crypto Push

8 sept. 2025, 17:01 UTC

Principaux Mouvements du Marché

Tron Shares Rise After New Investment From Bravemorning

8 sept. 2025, 16:14 UTC

Principaux Mouvements du Marché

Beyond Air Shares Climb on FDA Orphan Drug Designation for Brain Cancer Treatment

8 sept. 2025, 16:13 UTC

Principaux Mouvements du Marché

Dianthus Shares Whipsaw on Strong Trial Results, Safety Concerns

8 sept. 2025, 23:12 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

8 sept. 2025, 23:12 UTC

Market Talk

Global Equities Roundup: Market Talk

8 sept. 2025, 23:12 UTC

Market Talk

Infratil's New Bull Likes Exposure to Growing Infrastructure Businesses -- Market Talk

8 sept. 2025, 22:56 UTC

Market Talk

Worst May Be Over for New Zealand Retailers -- Market Talk

8 sept. 2025, 22:23 UTC

Market Talk

Ebos's Near-Term Earnings Outlook Dims -- Market Talk

8 sept. 2025, 21:51 UTC

Market Talk

AT&T Backs Outlook After EchoStar Spectrum Purchase -- Market Talk

8 sept. 2025, 21:47 UTC

Principaux Mouvements du Marché

Microsoft Signs $17.4B AI Deal With Nebius

8 sept. 2025, 21:33 UTC

Acquisitions, Fusions, Rachats

This Quantum Pure Play Is Going Public. What Infleqtion Does Differently, Says Its CEO. -- Barrons.com

8 sept. 2025, 21:20 UTC

Acquisitions, Fusions, Rachats

MEG Energy Plans to Respond on or Before Sept 15 >MEG.T

8 sept. 2025, 21:19 UTC

Acquisitions, Fusions, Rachats

MEG Energy Special Committee and Board Will Evaluate Revised Strathcona Offer >MEG.T

8 sept. 2025, 21:18 UTC

Acquisitions, Fusions, Rachats

MEG Energy Acknowledges Strathcona's Intention to Revise Offer

8 sept. 2025, 20:50 UTC

Market Talk
Acquisitions, Fusions, Rachats

Tech, Media & Telecom Roundup: Market Talk

8 sept. 2025, 19:33 UTC

Market Talk

Oil Futures Gain Despite Planned OPEC+ Output Increases -- Market Talk

8 sept. 2025, 19:22 UTC

Market Talk

U.S. Natural Gas Futures Settle Higher -- Market Talk

8 sept. 2025, 19:02 UTC

Market Talk

Dollar Lukewarm Amid Data Hiatus Ahead of August CPI -- Market Talk

8 sept. 2025, 18:24 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

8 sept. 2025, 18:24 UTC

Market Talk

Weaker Argentine Peso Profitable for Grain Producers -- Market Talk

8 sept. 2025, 17:29 UTC

Market Talk

Mexican Inflation Seen Little Changed in August -- Market Talk

8 sept. 2025, 16:59 UTC

Market Talk
Acquisitions, Fusions, Rachats

SpaceX Spectrum Acquisition Will Create More Satellite Connection Supply, Verizon CEO Says -- Market Talk

8 sept. 2025, 16:36 UTC

Market Talk

Crude Futures Hold Gains After OPEC+ Output Decision -- Market Talk

8 sept. 2025, 16:20 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

8 sept. 2025, 16:16 UTC

Résultats

Strategy Stock May Not Ever Make It Into the S&P 500 Index -- Barrons.com

8 sept. 2025, 16:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

8 sept. 2025, 16:04 UTC

Market Talk

Global Equities Roundup: Market Talk

Comparaison

Variation de prix

PureTech Health Plc prévision

Note du Consensus

By TipRanks

0 ratings

0

Achat

0

Maintien

0

Vente

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos PureTech Health Plc

PureTech Health plc, engages in the development and commercialization of biotechnology and pharmaceutical solutions in the United States. The company is developing LYT-100, which is under Phase 2 stage, to treat idiopathic pulmonary fibrosis (IPF); and LYT-200, a IgG4 monoclonal antibody, currently under Phase 1/2 stage, targeting galectin-9 for treating solid tumors and hematological malignancies. It also develops SPT-300, an oral drug of allopregnanolone for the treatment of anxious depression; SPT-320, a novel prodrug of agomelatine for the treatment of generalized anxiety disorder; and SPT-348, a prodrug of a non-hallucinogenic neuroplastogen for the treatment of mood and other neuropsychiatric disorders. In addition, the company is developing hydrogels to enable the oral administration of peptide therapeutics in preclinical development. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.
help-icon Live chat